PAD Day will return for a third year at CIRSE, exploring all aspects of peripheral arterial disease and its treatment. As part of this micro-track, the FIRSE@CIRSE session will provide a stage for the latest evidence from PAD trial and studies. Further highlights will include a controversy session on drug-based technology, a hot topic symposia on vessel preparation prior to drug delivery, and expert round tables on acute limb ischaemia and acute mesenteric ischaemia.
Arterial interventions
Don’t miss these exciting sessions!
Prof. Daniel van den Heuvel spoke to us on his presentation during the focus session on deep venous arterialisation for no-option CLTI patients. Scroll on to read the interview and browse some of the arterial track’s most interesting sessions!
FS 2807 – Deep venous arterialisation for no-option CLTI patients
Available on demand from September 23!
- What is the current evidence for DVA?
D. Van den Heuvel (Nieuwegein/NL) - The ideal patient and expected outcome
C. Del Giudice (Paris/FR) - Technical approach
R. Ferraresi (Bergamo/IT) - Open questions in DVA
S. Kum (Singapore/SG)
FP 501 – FIRST@CIRSE – First data release on endovascular research
Saturday, September 25, 16:00-17:00 CEST
- The novel temporary Spur stent system used in conjunction with a commercially available, paclitaxel-coated balloon: 6-months results of the DEEPER OUS trial
M. Lichtenberg (Arnsberg/DE) - Treatment of venous iliofemoral occlusive disease with the Venovo self-expanding venous stent: 36-months results from the prospective, multicenter VERNACULAR trial
M. Dake (Tucson, AZ/US) - Prospective first in man study of the Merit WRAPSODY™ endovascular stent graft for treatment of access circuit outflow stenosis in hemodialysis patients
J. Gilbert (Oxford/GB)
HTS 401 – PAD Day: Vessel preparation prior to drug delivery – when and how
Saturday, September 25, 14:30-15:30 CEST
- Vessel preparation: when to do it
S. Müller-Hülsbeck (Flensburg/DE) - Standard angioplasty
K. Katsanos (Patras/GR) - Atherectomy
E. Blessing (Karlsbad/DE) - Plaque scoring
R. E. Beasley (Miami/US) - Intravascular lithotripsy
A. Holden (Auckland/NZ) - Laser
C. Wissgott (Rendsburg/DE)
CS 201 – PAD Day: Drug-based technology – controversy between evidence and perception
Saturday, September 25, 11:30-12:30 CEST
- Paclitaxel-based technologies are dangerous – pro
M. Lee (Dublin/IE) - Paclitaxel-based technologies are dangerous – con
G. Tepe (Rosenheim/DE) - Drug-dosage is irrelevant – pro
C. Pena (Miami/US) - Drug-dosage is irrelevant – con
E. A. Secemsky (Boston/US) - Sirolimus will replace paclitaxel – pro
T. Albrecht (Berlin/DE) - Sirolimus will replace paclitaxel – con
M. Palena (Cotignola/IT)